News

INC raises its 2015 expectations after another strong quarter

CRO INC Research posted another quarter of double-digit revenue growth, lifting its 2015 guidance for the second time to account for a jump in new business.

Patheon unloads some assets on the way to an IPO

Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO.

Covance names a new CEO as it adjusts to life with LabCorp

Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.

Charles River's revenue slips on slumping R&D demand

Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.

PRA boosts its profit forecast after a strong sales quarter

PRA Health Sciences is ticking up its full-year expectations after another quarter of revenue growth, counting on a steady stream of new business.

Icon dials back its guidance after posting modest sales growth

Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.

Quintiles restores its rosy outlook after a big quarter

Quintiles is going back to its earlier optimism for 2015, scaling up its previously reduced growth projections after posting a strong sales quarter.

Avista buys another pharma contracting biz

Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.

Covance and LabCorp open a new R&D center to pool their expertise

Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.

PRA doubles down on the hunt for new R&D talent

PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.

Huntingdon and Harlan raise up to $125M to fund their future together

The recently merged Huntingdon Life Sciences and Harlan Laboratories have convinced their investors to commit up to $125 million in equity financing, lining up the cash they'll need to move forward as a joint entity.

Biocon might spin out its CRO after taking it public

Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.

AMRI bets $174M on manufacturing with latest buyout

Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.

Almac settles into Singapore with eyes on Asian expansion

Contract drug developer Almac has opened a new shop in Singapore, a facility that will serve as the company's Asian headquarters as it plots more investments in the region.

Icon and Covance bet on diagnostics with a pair of cancer deals

CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.

Aptuit scales up its production prowess for Phase III trials

Contract drug developer Aptuit has bolstered its in-house production capabilities and can now churn out doses for Phase III trials, a move the company says was motivated by client demand.

Under new ownership, Synexus expands across Europe

Patient recruitment specialist Synexus has opened up new outposts across Eastern Europe, following through on its promise to expand around the globe after changing hands for $128 million.

Frontage buys into biometrics with BDM deal

CRO Frontage Laboratories has acquired a 45% stake in New Jersey's BDM Consulting, a biometrics-focused company looking to expand the market for its data services.

WuXi bets $50M on a new venture fund and eyes $200M more

Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.

Recipharm takes a 25% stake in its drug-developing partner

Swedish contractor Recipharm has deepened its ties with partner Pharmanest, taking up a 25% stake in the biotech as the two collaborate on a pain drug.